| 
 | 
Active Org.-  | 
Originator Org.-  | 
Active Indication-  | 
Inactive Indication-  | 
Drug Highest PhaseClinical  | 
First Approval Ctry. / Loc.-  | 
First Approval Date20 Jan 1800  | 
100 Clinical Results associated with TMEFF2 x CD3ε
100 Translational Medicine associated with TMEFF2 x CD3ε
0  Patents (Medical) associated with TMEFF2 x CD3ε